MONARCH
The MONARCH Study is now enrolling.
MAFLD (metabolic dysfunction - associated fatty liver disease) defines a range of conditions characterized by an increased amount of fat in the liver. MAFLD can develop into metabolic dysfunction - associated steatohepatitis (MASH), which is characterized by inflammation and fibrosis. If you have been diagnosed with MAFLD, MASH or liver fibrosis you may be eligible to participate in a clinical study evaluating an investigational treatment.
To see if the MONARCH Study is right for you, please contact us below.
Location: MNGI Digestive Health, Northeast Minneapolis Clinic
Physician Investigator: Dr. Hanouneh
Study Coordinator: Naomi Mugarura
Boehringer Ingelheim 1404-0044
We are looking for individuals who have been diagnosed with NASH/MASH to take part in a research study for an investigational medication. The study is testing whether the investigational medication will help people with NASH/MASH who have moderate or advanced liver fibrosis.
You may qualify if:
- You are 18 years of age or older,
- Have been diagnosed with NASH/MASH with moderate or advanced liver fibrosis, and
- Are willing to maintain a stable diet and physical activity levels during participation.
Participants will receive the study medication and all related study procedures that are required at no cost. Participants may be reimbursed for travel and time commitment. To see if this study is right for you, please contact us.
Location: MNGI Digestive Health, Northeast Clinic.
Physician Investigator: Ibrahim Hanouneh, MD
Study Coordinator: Jennifer Burdick